BKHAU News | Roxom Stocks

Invest Private Security Newsroom

Market Overview

Indices and commodities.

Bitcoin treasury preferreds.

The artificial intelligence theme.

Bitcoin Treasuries

Companies holding bitcoin.

Sectors, global markets and rates.

Popular Portfolios

13F filings, smart money.

Borrow USDT or USDC against your BTC without giving it up.

Switch your bitcoin-backed loan and pay less interest.

Borrow, invest, keep the spread.

Stock Dividends

Dividends from tokenized equities.

Company

Our leadership team, mission, and investors.

Vision, purpose, and architecture behind Roxom.

Terms, privacy, and disclosures.

Resources

Guides, FAQs & support.

Trading logic, platform rules, and fundamentals.

Connect, authenticate, and build with our API.

Current platform health and incidents.

Loading chart

Pay with

1 BTC

=

- USD

Loading market data...

Loading chart

Pay with

BK

Loading chart

BK

BKHAUBlack Hawk Acquisition Corporation Units

BKHAU

Pay with—

Available Balance0.00

BK

Mkt Cap

N/A

Volume

N/A

Next Earnings

N/A

Chart Earnings News About Insider Filings

Vesicor Therapeutics Appoints Michael Tolentino, M.D., as Chief Executive OfficerVesicor Therapeutics, a biotech company developing p53-based cancer therapeutics, announced the appointment of Michael Tolentino, M.D. as Chief Executive Officer effective March 17, 2026. Tolentino, a serial entrepreneur with over 20 years of biotech experience, succeeds founder Luo Feng who transitions to Chief Scientific Officer. The leadership change comes as Vesicor prepares to complete its proposed de-SPAC merger with Black Hawk Acquisition Corporation and accelerate IND-enabling studies with an FDA submission targeted for 2027.GlobeNewswire Inc. · Mar 19, 2026

Vesicor Therapeutics, Inc. and Black Hawk Acquisition Corporation Enter into a Business Combination Agreement to Create a Biotechnology Company Advancing p53-based Cancer Therapeutics Delivered Via MicrovesiclesVesicor Therapeutics, a biotechnology company focused on p53-based cancer therapeutics, has entered into a business combination agreement with Black Hawk Acquisition Corporation to create a public company advancing its drug candidate.Benzinga · Apr 28, 2025

CORRECTION: Black Hawk Acquisition Corporation Welcomes Mr. Jonathan Ginsberg to BoardDANVILLE, Calif., April 23, 2024 (GLOBE NEWSWIRE) -- In a release issued under the same headline earlier today by Black Hawk Acquisitions Corporation (NASDAQ: BKHAU), please note that the second paragraph reference to Mr. Ginsberg meeting "the independent director standards of The Nasdaq Stock Market" has been removed. The corrected release follows:GlobeNewswire Inc. · Apr 24, 2024

Black Hawk Acquisition Corporation Welcomes Mr. Jonathan Ginsberg to BoardDANVILLE, Calif., April 23, 2024 (GLOBE NEWSWIRE) -- Black Hawk Acquisition Corporation (NASDAQ: BKHAU, the "Company") announced today the appointment of Mr. Jonathan Ginsberg, age 33, to serve as a director of the Company and its Chief Operating Officer.GlobeNewswire Inc. · Apr 23, 2024

Black Hawk Acquisition Corporation Announces Closing of $69,000,000 Initial Public OfferingDANVILLE, Calif., March 22, 2024 (GLOBE NEWSWIRE) -- Black Hawk Acquisition Corporation (NASDAQ: BKHAU, the “Company”) announced today that it has closed its initial public offering of 6,900,000 units at $10.00 per unit. Each unit consists of one share of common stock and one-fifth (1/5) of one right to receive one share of common stock upon the consummation of an initial business combination.GlobeNewswire Inc. · Mar 22, 2024

to start trading

BK

BKHAUBlack Hawk Acquisition Corporation Units

BKHAU

Pay with—

Available Balance0.00

Your PositionYou don't own any BKHAU yet.

Related Tickers

Earnings